Oxyrane UK ^Company

Oxyrane UK Limited is a biopharmaceutical company dedicated to developing novel enzyme replacement therapies to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. The company's enzyme therapies are engineered in a way to enhance their targeting and activity. This is achieved using Oxyrane's proprietary engineered yeast expression technology that produces proteins with defined human phosphoglycosyl structures required for effective intracellular uptake and localization. Oxyrane's enzymes have the potential to be significantly more effective than first-generation ERTs, because of the technology's ability to phosphorylate glycans on any glycosylation site ensuing in higher levels of mannose-6-phosphate on the enzyme, permitting more efficient uptake into cells and subsequent targeting to lysosomes. The company's yeast engineering technology has produced several engineered proteins, including enzymes deficient in other LSDs, antibodies and other proteins. Oxyrane's engineering technology ensures batch-to-batch product consistency for the enzymes and their sugar structures under various culture conditions.